ML-007
Schizophrenia (negative symptoms)
Key Facts
About MapLight Therapeutics
MapLight Therapeutics is on a mission to redefine the standard of care for brain disorders by moving beyond broad neuromodulation to precise, circuit-specific therapeutics. The company has built a robust pipeline of six drug candidates, with its most advanced programs in Phase 2 trials for schizophrenia and Alzheimer's disease psychosis. Its strategy is anchored in a proprietary discovery platform co-founded by optogenetics pioneer Karl Deisseroth, which integrates cutting-edge technologies to translate deep neuroscience insights into targeted medicines for conditions like autism, Parkinson's, and schizophrenia.
View full company profileAbout MapLight Therapeutics
MapLight Therapeutics is on a mission to redefine the standard of care for brain disorders by moving beyond broad neuromodulation to precise, circuit-specific therapeutics. The company has built a robust pipeline of six drug candidates, with its most advanced programs in Phase 2 trials for schizophrenia and Alzheimer's disease psychosis. Its strategy is anchored in a proprietary discovery platform co-founded by optogenetics pioneer Karl Deisseroth, which integrates cutting-edge technologies to translate deep neuroscience insights into targeted medicines for conditions like autism, Parkinson's, and schizophrenia.
View full company profileTherapeutic Areas
Other Schizophrenia (negative symptoms) Drugs
| Drug | Company | Phase |
|---|---|---|
| Roluperidone (MIN-101) | Minerva Neurosciences | Phase 3 |
| Vafidemstat (ORY-2001) | Oryzon Genomics | Phase IIa |